Incyte Corp has earned a $25 million milestone payment from Novartis, triggered by the EMA’s positive opinion for Jakavi (ruxolitinib) for the treatment of adult patients with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea.   Under the collaboration and license agreement signed in 2009, Novartis has exclusive development and commercialization rights to ruxolitinib outside of the U.S. for all hematologic and oncologic indications, and sells ruxolitinib under the name Jak...